22:01 on June 21, 2022, Beijing time, Sangamo Therapeutics Inc (SGMO.us) shares fluctuated, rising 10.28%. As of press time, the stock was trading at US $3.95 per share, with a turnover of 386091 shares, a turnover rate of 0.26% and an amplitude of 9.78%.

Recent financial data show that the unit has an operating income of $28.23 million.Net profit-$43.98 million, earnings per share-$0.30Gross profit25.40 million US dollars, with a price-earnings ratio of-3.25 times.

In terms of agency ratings, of all the 11 agencies that participated in the rating, 73% of the brokerages gave buy advice, 27% gave hold advice and no brokerage gave sell advice.

The biotech industry in which Sangamo Therapeutics Inc shares are located rose 2.52 per cent as a whole. Among its related stocks, Valneva Se, Clovis Oncology Inc and Innate Pharma rose significantly, while Mereo Biopharma Group Plc, Clovis Oncology Inc and Arcadia were more active, with turnover rates of 12.57%, 9.89% and 5.02% respectively. The related stocks with larger amplitudes were Lava Therapeutics Nv, Clovis Oncology Inc and Dermata Therapeutics Inc, with amplitudes of 36.84%, 29.66% and 23.56%, respectively.

About Sangamo Therapeutics Inc: Sangamo Therapeutics Inc is a company founded in Delaware on June 22nd, 1995. The company's main business is to transform groundbreaking science into gene therapy by using the company's platform technology in gene editing, gene therapy, gene regulation and cell therapy to improve the quality of life of patients. The company's proprietary zinc finger DNA binding protein technology enables effective and highly specific gene editing and regulation. In addition, the company is developing gene editing and gene therapy for genetically traceable diseases.

(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )